Orca-T Reduces GVHD, Improves GVHD-Free RFS in Posttransplant Setting Across Hematologic Cancers
January 28, 2022
Arpita Gandhi, M.D., participates in an OncLive Q&A on the background of Orca-T, a type of high-precision allogeneic cellular therapy and how this type of treatment could revolutionize outcomes for patients with serious hematologic malignancies.